Dr. Jaume Pons served as the CEO of ALX Oncology Holdings Inc. from December 22, 2020, until September 6, 2023, when he transitioned to the role of Chief Scientific Officer and President. Under his leadership, the company focused on developing...

Dr. Jaume Pons served as the CEO of ALX Oncology Holdings Inc. from December 22, 2020, until September 6, 2023, when he transitioned to the role of Chief Scientific Officer and President. Under his leadership, the company focused on developing innovative cancer therapies, demonstrating a strong commitment to pushing boundaries in biotechnology. In 2023, Dr. Pons had a total compensation of $1 million, with a salary of $649,740 and a bonus linked to corporate performance. He also managed significant stock holdings, reflecting his belief in the company's potential, though these holdings experienced fluctuations over time, peaking in late 2020. His tenure was marked by notable insider trading activity, with transaction values reaching over $45 million in December 2020 alone. Dr. Pons has been recognized for his significant contributions to the biotech field and remains instrumental in the scientific direction of ALX, showing a blend of leadership and research expertise that guides the company forward.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other ALX Oncology Holdings Inc. CEOs

A

Dr. Jaume Pons

Ex-CEO of ALX Oncology Holdings Inc.

Sector of Economy

Healthcare

CEO of ALX Oncology Holdings Inc. for

2 years 8 months (Dec 2020 - Sep 2023)

Previous Experience

President and Chief Executive Officer of ALX Oncology Holdings Inc.

Rivals

Competitors/colleagues of Dr. Jaume Pons

Holdings

See how much did Dr. Jaume Pons make over time.

Dr. Jaume Pons had significant holdings in ALX Oncology shares during his time as CEO. His wealth mostly reflected his commitment to the company, experiencing interesting fluctuations in value. At its highest point in December 2020, his holdings were valued...

Dr. Jaume Pons had significant holdings in ALX Oncology shares during his time as CEO. His wealth mostly reflected his commitment to the company, experiencing interesting fluctuations in value. At its highest point in December 2020, his holdings were valued around $45 million. However, over the subsequent years, these values fluctuated with the stock market, reflecting the typical volatility that can occur in biotech sectors. Pons' approach to insider trading showed activity that often aligned with company performance, as he navigated significant market changes. His stock exposure indicates a deep belief in the company's mission and its future value in the market.

Total Stock Sold

$10.83M

ALXO

$10.83M

318,736 ALXO shares

What if they kept their stock?

If Dr. Jaume Pons didn't sell their stock, today they would have:
Extra ALXO318,736 shares worth $9.56M.
This is -11.72% and $1.27M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Dr. Jaume Pons.

ALXO

$1.53K

ALXO at $1.15/share

Feb 19, 2025

Sale

ALXO

$17.06K

ALXO at $1.58/share

Dec 30, 2024

Sale

ALXO

$5.00K

ALXO at $2.58/share

Aug 14, 2024

Sale

ALXO

$158.08K

ALXO at $7.90/share

Jul 11, 2024

Sale

ALXO

$62.60K

ALXO at $5.82/share

Jul 1, 2024

Sale

ALXO

$168.65K

ALXO at $8.43/share

Jun 4, 2024

Sale

ALXO

$318.33K

ALXO at $15.92/share

May 6, 2024

Sale

ALXO

$710.20K

ALXO at $14.20/share

Apr 16, 2024

Sale

ALXO

$223.04K

ALXO at $11.15/share

Apr 4, 2024

Sale

ALXO

30,000 shares

ALXO

Feb 14, 2024

Received

Compensation History

See how much did Dr. Jaume Pons make over time.

In 2023, Dr. Jaume Pons received a total compensation package of $1 million as CEO of ALX Oncology Holdings Inc., which included a base salary of $649,740 and a performance-based bonus of $357,357, representing 55% of his salary based on reaching corporate goals. His previous years also showed substantial compensation, including a total of $3.7 million in 2022, largely driven by stock options and bonuses tied to the company's performance. Over his time as CEO, his compensation reflected his role's alignment with the company's strategic direction and growth in the competitive biotechnology market. His compensation plan was built to incentivize long-term growth and shareholder value, reinforcing his commitment to the company's success.

Year

2023

Total Compensation

$1.79M

Salary

$649.74K

Board Justification

The compensation philosophy is designed to attract, engage, and retain executive officers while aligning their interests with those of stockholders through performance-based incentives.

Bonus

$357.36K

Board Justification

The annual target bonus for Dr. Pons was set at 55% of his annual base salary, based on the achievement of corporate goals for 2023.

Other

$0.00

Board Justification

No additional compensation was reported for Dr. Pons in 2023.

Restricted Stock

$779.00K(521.54K RSU)

Board Justification

The value of stock awards that vested in 2023, calculated based on the fair value at the time of vesting.

Performance Metrics

The performance metrics for Dr. Pons' compensation were based on corporate goals related to specific programs, trials, and corporate progress.

Other ALX Oncology Holdings Inc. CEOs

Here are other CEOs of ALX Oncology Holdings Inc.

Jason Lettmann

CEO of ALX Oncology Holdings Inc.

September 2023 - Present